Stockreport

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

60 Degrees Pharmaceuticals, Inc.  (SXTP) 
PDF Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary [Read more]